Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

table HBV DNA. These results were statistically significant compared to placebo. In addition to the potent antiviral suppression, 16% of the HBeAg- patients who received clevudine demonstrated a sustained virologic response (SVR) 24 weeks after stopping therapy, versus 0% of the patients who had received the placebo. In Study 303, a South Korean open-label, follow-on study of clevudine, Bukwang observed similar findings. 80% of HBeAg- patients had undetectable HBV DNA 12 weeks after completing a 48-week course of therapy.

Clevudine was generally safe and well-tolerated by patients with chronic HBV. There was no meaningful difference between clevudine and placebo in the incidence of serious adverse events during treatment in Studies 301 and 302 and during follow-up except that a higher percentage of placebo-treated patients had elevated liver enzyme levels than patients treated with clevudine.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Contact

Kurt Leutzinger

Chief Financial Officer


SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 For the pharmaceutical industry, marketplace success ... payers. Likewise, the importance of the managed markets function - ... to grow as payer formularies and provider networks play an ... At the same time, managed markets leaders must continually identify ...
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... recent study conducted by oculoplastic surgeon Charles Soparkar, ... a patent-pending formulation of zinc and phytase (trademarked ... oral administration for 4 days prior to a ... duration in 41 of 44 patients tested (93%). ...
... ABT ) announced today it has received approval from the U.S. ... e HBV assay for measuring viral load or the amount of ... first and only approved test capable of automating HBV viral load ... Abbott RealTi m e HBV assay, based on real-time PCR (polymerase ...
Cached Medicine Technology:Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 3Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 4
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... Orderly Sale and Disposition of Hospital Assets,Patient Care to ... 24 Hospital Partners of America,("HPA" or "the Company") ... voluntary petitions of reorganization under Chapter 11,of the U.S. ... of,any of the hospitals in the HPA system, which ...
... LLC, founded,by Dr. Debbie Badawi, is an independent ... is focused on strengthening, empowering, and,rejuvenating families., ... 14-plus,years working with families, and my educational and ... unique needs," said Dr. Badawi.,"PeopleClick provides parents and ...
... be Bestowed , ... Nashville, TN (Vocus) September 24, ... academic year on Monday, September 29 at 9 a.m. with an ... Convocation. The first two non African-American graduates of Meharry will ...
... giant leaps for mankind through thousands of NASA innovations.,The ... industry businesses and advocacy groups, announced today the release ... Jr., who was the first African American to walk ... payload commander on two Space Shuttle flights. Dr. Harris ...
... Sept. 24 In response to,"Caffeinated Energy Drinks ... published,in the journal Drug and Alcohol Dependence, the ... "It,s unfortunate that the authors of this article ... a rhetorical attack when the facts of,their review ...
... and Elizabeth Medical Center, CHICAGO, Sept. 23 ... 2233 W. Division Street, is offering a,Coronary Calcium CT ... months,of October and November. A $500 value, this screening ... CT scanner, an,electrocardiogram and measurement of blood pressure, glucose ...
Cached Medicine News:Health News:Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities 2Health News:PeopleClick, LLC Provides Cutting-Edge Servicing to Parents and Families 2Health News:First Two Non African-American Graduates of Meharry Medical College to Receive Awards at 2008 Fall Convocation 2Health News:First Two Non African-American Graduates of Meharry Medical College to Receive Awards at 2008 Fall Convocation 3Health News:First Two Non African-American Graduates of Meharry Medical College to Receive Awards at 2008 Fall Convocation 4Health News:Advancing Medical Technology from Space 2Health News:American Beverage Association Statement on Caffeinated Energy Drinks 2Health News:Heart CT Scan Helps Find Coronary Artery Disease 2
Inquire...
... Designed for the scientist who wants ... the TE2000E2 is a high precision Z-focus ... This makes it possible to expand ... sources and image outputs. A five-way ...
... the most advanced motorized inverted microscope from ... optical design provides 9 access ports for ... four ports can have simultaneous access to ... Z-axis drive, 6-position nosepiece and light path ...
... exceptional performance for diverse applications ... unrivaled fluorescence imaging capabilities equal ... Developed for the highest fluorescence ... first-class optical illumination systems for ...
Medicine Products: